The study was stopped at the interim analysis for futility.
Dr. McGowan said the study was stopped because of the serious questions about the hormone's safety.
The data were compelling enough that the study was stopped early by a data monitoring committee.
The results were so shocking that the study was stopped in 2002.
The study was stopped immediately and all participants were taken off the drug.
The study was stopped early because of the obvious futility of the intervention.
Because defibrillators appeared to extend patients' lives, the study was stopped early, and all participants were offered free defibrillators.
Pfizer, which financed the research, said the Lipitor portion of the study was stopped because the drug demonstrated a significant benefit.
The study was stopped early, after 6.8 years, because there was an increased risk of stroke in the women taking estrogen.
The study was stopped early when it became apparent that those taking hormones had a small increase in the risk of breast cancer.
The study was stopped earlier than planned following two serious adverse events (syncope due to orthostatic hypotension) occurring during ketamine infusion.
